reports
Cerulean Pharma and Daré Bioscience Announce Closing and New Stock Sy...
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU) and Daré Bioscience Operations, Inc. (formerly Daré Bioscience, Inc.) today announced the closing of the transactions contemplated by the stock purchase agreement entered into by the companies on March 19, 2017. As a result of these transactions, (i) the former holders of Daré equity securities now hold approximately 51% of Cerulean capital stock (calculated based on the stock purchase agreement), (ii) Daré Bioscience Operations, Inc. has become a wholly-...
Daré Bioscience Distributes Letter to Cerulean Stockholders Outlining...
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU) and Daré Bioscience, Inc. today announced that Daré Founder and CEO Sabrina Martucci Johnson mailed the following letter to Cerulean stockholders of record at the close of business on June 9, 2017 outlining the Daré value proposition and requesting they vote FOR all of the management proposals at the upcoming special meeting of stockholders to be held on July 19, 2017: Dear Cerulean Stockholder, As the founder and CEO of Daré Bioscience,...
Cerulean Urges Stockholders to Vote for Proposals at July 19, 2017 Spe...
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU) today urged stockholders of record at the close of business on June 9, 2017 to vote FOR all of the proposals at the upcoming special meeting of stockholders to be held on July 19, 2017. Each of the proposals is an important element of Cerulean’s plan to maximize stockholder value. On February 1, 2017, Cerulean announced its board of directors had initiated a review of strategic alternatives which could result in changes to its business strategy and future ...
Cerulean Distributes Letter to Stockholders Requesting Favorable Vote ...
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU) today announced that the company mailed the following letter from President and Chief Executive Officer Christopher D. T. Guiffre to the company’s stockholders of record at the close of business on June 9, 2017, requesting they vote “for” all of the management proposals at the upcoming special meeting of stockholders to be held on July 19, 2017: Dear Fellow Cerulean Stockholder: Cerulean Pharma Inc. (“Cerulean”) respectfully requests your vote in ...
Cerulean and Daré Announce Awards for Daré CEO
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), and Daré Bioscience, Inc., a privately-held, clinical-stage healthcare company advancing products for women’s reproductive health, today announced that Sabrina Martucci Johnson, Daré Founder and CEO, is receiving two awards. Ms. Johnson was honored by Athena, a San Diego-based business organization championing women executives and rising managers in science, technology, engineering and mathematics. “Recipients of the 2017 Pinnacle Awards represe...
Cerulean and Daré to Host Conference Call on Proposed Transaction on ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), today announced jointly with Daré Bioscience that the companies will hold a joint conference call to discuss the definitive share purchase agreement under which the stockholders of Daré Bioscience will become the majority owners of Cerulean. The conference call will take place at 9:00 a.m. ET on Thursday, March 23, 2017. This call can be accessed by dialing 443-637-1284 or 844-831-3031 prior to the start of the call and referencing conference ...
Cerulean Pharma and Daré Bioscience Enter into Stock Purchase Agreeme...
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU) and Daré Bioscience, Inc., a privately-held, clinical-stage pharmaceutical company advancing products for women’s reproductive health, today announced that the two companies, together with the equityholders of Daré Bioscience, have entered into a definitive stock purchase agreement under which the equityholders of Daré Bioscience will become the majority owners of Cerulean. The transaction and the Cerulean asset sales mentioned below would result in a NASDAQ...
Cerulean Announces Review of Strategic Alternatives
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that its Board of Directors is conducting a comprehensive review of strategic alternatives focused on maximizing stockholder value. Cerulean has engaged investment bank, Aquilo Partners, L.P., as its financial advisor to assist in the strategic review process. The intention of the strategic review is to evaluate potential alternatives such as the sale of the company, a ...
Cerulean Reports Third Quarter 2016 Financial Results and Provides Cor...
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities for the quarter ended September 30, 2016. “Cerulean experienced a clinical setback in the third quarter, but in October we demonstrated the promise of our NDC platform when we announced a collaboration with Novartis Institutes for BioMedical Research, Inc. (Novartis),” said Christopher D. T. Guiffre, President and Chief Executive ...
Cerulean to Host Third Quarter 2016 Conference Call on November 3
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities for the third quarter 2016 on November 3. Management will conduct a conference call at 4:30 p.m. ET that day to provide a business update and review the Company’s third quarter financial results. This call can be accessed by dialing (844) 831-3031 or (443) 637-1284 prior to the start of the call and referencing ...
Cerulean Announces Promotion of Scott Eliasof, PhD to Senior Vice Pres...
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that Scott Eliasof, PhD, has been promoted to the role of Senior Vice President and Chief Scientific Officer, effective immediately. Dr. Eliasof joined Cerulean in 2007 and was appointed Vice President of Research in 2011. “For the past ten years, Scott has been one of the driving forces behind our NDC innovations, and we are pleased to expand his role at this cr...
Cerulean Announces Technology Platform Collaboration
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the Company has entered into a strategic collaboration with Novartis to develop NDC product candidates combining Cerulean’s proprietary Dynamic Tumor Targeting™ technology with Novartis’ proprietary compounds directed at up to five targets. Cerulean will create NDC candidates, and Novartis is responsible for further development and commercialization of NDC products r...
Cerulean Announces $20 Million Firm Commitment At-The-Market Stock Pur...
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that it has entered into a $20 million common stock purchase agreement (Purchase Agreement) and a registration rights agreement (Registration Rights Agreement) with Aspire Capital Fund, LLC (Aspire), a Chicago-based institutional investor. These agreements constitute a firm commitment at-the-market equity facility. Immediately following the execution of the Purchase Agree...
Cerulean Announces Data Presentations at the 2016 European Society for...
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will present clinical data from its CRLX101 and CRLX301 programs at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting being held in Copenhagen, Denmark on October 7-11. Details of the ESMO poster presentations are as follows: Title: A phase 1b/2 study of the nanoparticle-drug conjugate CRLX101 in combination with weekly paclitaxel in patient...
Update: Update on ovarian cancer and CRLX301
Cerulean recently presented the results on the Phase Ib trial of CRLX101 with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer. The nine-patient trial showed a 56% overall response rate (ORR). The company also reported data from the Phase I/IIa dose escalation trial of CRLX301 (docetaxel nanoparticle conjugate) for solid tumors. The primary purpose of the study was to determine the maximum tolerated dose, but six of the 13 patients evaluable for efficacy were stabilized d...
Update: Phase II renal data pushed to Q3 from Q2
Cerulean reported first quarter results and provided a pipeline update on 2 May, while confirming an expected cash runway for the company into 2017. Management has pushed back its timing for an announcement on the highly awaited top-line data for CRLX101 in renal cancer. Critical Phase II top-line data in RCC are now expected in Q316 (changed from end-June), due to an apparent slowing of the rate of disease progression in patients.
Update: Approaching release of Phase II renal data
On 10 March Cerulean reassured the market by reporting in-line full-year 2015 results, reiterating an expected cash runway into 2017 and confirming timelines for releasing clinical data for key pipeline projects in H116 are on track. Phase II data in renal cancer are expected by end June for its high-profile CRLX101, which uses its nanoparticle drug delivery system.
Update: Collaborating with big pharma
Cerulean reported in-line Q3 results on 16 November followed by an investor call highlighting its growing clinical program for treatments using its unique nanoparticle drug conjugation NDC delivery system. If successful, lead compound CRLX101 will launch as a new mechanism of action in third- and fourth-line renal cell cancer where there are few treatment options. Its technology holds the potential for numerous NDC combinations with currently marketed drugs, underlined by its newly announced col...
Initiation: Multiple price inflections on clinical pipeline
Cerulean is on track to announce critical Phase II trial results for CRLX101 in metastatic renal cancer (mRCC) in H116 following encouraging preliminary efficacy data in a Phase IIa readout presented at ASCO in 2015. Additionally, interim Phase Ib/II results are due for CRLX101 in ovarian and rectal cancers in H215 and Phase I data for CRLX301 in 2015 in solid tumors. If positive, these results should renew confidence in Cerulean’s pipeline and its differentiated nanoparticle drug conjugate te...
QuickView: Multiple data readouts in coming quarters
In its Q2 results on 6 August, Cerulean confirmed its clinical programme is progressing to plan and continues to expect numerous critical data readouts over the next 12 months. Most notably, results from its Phase II trial of CRLX101 in renal cell cancer (RCC) will be announced in Q216 while initial clinical data for CRLX301 are expected in Q4 of this year. We highlight that recent announcements by two peers progressing first- and second-line treatments for RCC could bode well for CRLX101 as a l...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.